The last time I posted on Travere Therapeutics (TVTX), in September 2025, I gave the stock a buy rating. I was discussing the fact that the FDA had opted not to convene an Advisory Committee meeting ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”) ...

Travere cannot predict the magnitude of such market activity or the overall effect it will have on the price of the Notes or Travere’s common stock. J.P. Morgan, Jefferies, and Leerink Partners are ...

Hello, and welcome to Travere Therapeutics First Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi ...